Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation, others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
Molecular Weight:
445.388
CAS Number:
[1354567-82-0]
Formula:
C23H26Cl2N4O
Target:
FLT|||JAK|||CDK|||Others
* VAT and and shipping costs not included. Errors and price changes excepted
